Fighting to Preserve the Benefits of the 340B Program
RWC-340B releases press statement urging Congress to soundly reject House Republicans “340B Access Act”. “Disguised as a genuine reform effort, the bill would diminish the program’s benefits to favor drug…
Today, the D.C. Circuit Court of Appeals issued its decision regarding HRSA’s enforcement authority to prevent contract pharmacy restrictions imposed by Novartis and United Therapeutics. Novartis limits hospital covered entities…
RWC-340B carefully reviewed the draft legislation, explanatory statement, and supplemental request for information (RFI) that the Bipartisan 340B Senate Working Group (Working Group) shared with 340B stakeholders on February 2,…
Today, HHS published revised 340B administrative dispute resolution regulations (ADR Rule) that will replace existing ADR regulations effective June 18. Most notably, the ADR Rule does not include a proposal…
Beginning March 19, 2024, Amgen will apply its contract pharmacy restriction policy to all covered entity types, including previously exempted federal grantees. Amgen’s policy applies to self-administered Amgen products—Repatha®, Enbrel®,…
We are excited to announce that United Partners for Human Services, the managed service organization for RWC-340B has hired Michael D. Thompson, Pharm.D. as Managing Director for the Coalition. Starting…
RWC-340B welcomes the release of the bipartisan Senate Working Group on 340B’s legislative discussion draft of the “SUSTAIN 340B Act.” The draft bill – formally titled, the Supporting Underserved and Strengthening…
On January 24, 2024, RWC-340B sent a letter of support in connection with a False Claims Act case that, if successful, could clear a pathway for Ryan White clinics (RWCs)…
Gilead Expanded Policy Gilead expanded its existing restrictions on contract pharmacy arrangements, effective January 30, 2024, but only for covered entities that dispense 340B drugs through wholly-owned contract pharmacies. Gilead’s…
CMS published revised guidance on December 14, 2023 to defer its decision to require 340B point-of-sale modifiers for Part D drugs beginning in 2026. RWC-340B submitted comments to CMS’s initial proposal…